Anteris Technologies Future Growth

Future criteria checks 1/6

Anteris Technologies's earnings are forecast to decline at 11.2% per annum while its annual revenue is expected to grow at 10.3% per year. EPS is expected to grow by 7.1% per annum. Return on equity is forecast to be -261.6% in 3 years.

Key information

-11.2%

Earnings growth rate

7.1%

EPS growth rate

Medical Equipment earnings growth	16.7%
Revenue growth rate	10.3%
Future return on equity	-261.6%
Analyst coverage	Low
Last updated	08 Apr 2024

Recent future growth updates

No updates

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

Earnings and Revenue Growth Forecasts

ASX:AVR - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	6	-96	-82	-62	1
12/31/2025	6	-85	-72	-72	1
12/31/2024	6	-79	-57	-57	1
12/31/2023	4	-67	-55	-51	N/A
9/30/2023	4	-60	-50	-47	N/A
6/30/2023	4	-52	-45	-43	N/A
3/31/2023	5	-48	-43	-41	N/A
12/31/2022	5	-44	-40	-39	N/A
9/30/2022	6	-40	-37	-36	N/A
6/30/2022	7	-35	-34	-33	N/A
3/31/2022	7	-29	-27	-26	N/A
12/31/2021	8	-23	-20	-19	N/A
9/30/2021	7	-21	-16	-16	N/A
6/30/2021	6	-20	-12	-12	N/A
3/31/2021	7	-17	-13	-13	N/A
12/31/2020	7	-15	-14	-14	N/A
9/30/2020	9	-8	-6	-17	N/A
6/30/2020	10	0	2	-19	N/A
3/31/2020	14	-3	0	-21	N/A
12/31/2019	17	-6	-1	-23	N/A
9/30/2019	20	-15	-13	-24	N/A
6/30/2019	24	-24	-25	-24	N/A
3/31/2019	25	-24	-24	-23	N/A
12/31/2018	26	-24	-23	-22	N/A
12/31/2017	23	-17	-16	-13	N/A
6/30/2017	22	-12	N/A	-12	N/A
3/31/2017	21	-15	N/A	-16	N/A
12/31/2016	20	-18	N/A	-20	N/A
9/30/2016	17	-21	N/A	-21	N/A
6/30/2016	14	-24	N/A	-22	N/A
3/31/2016	13	-26	N/A	-23	N/A
12/31/2015	12	-27	N/A	-24	N/A
9/30/2015	11	-26	N/A	-23	N/A
6/30/2015	10	-25	N/A	-21	N/A
3/31/2015	9	-21	N/A	-19	N/A
12/31/2014	9	-17	N/A	-17	N/A
9/30/2014	8	-12	N/A	-14	N/A
6/30/2014	8	-7	N/A	-11	N/A
3/31/2014	8	-4	N/A	-8	N/A
12/31/2013	8	-1	N/A	-6	N/A
9/30/2013	8	-1	N/A	-5	N/A
6/30/2013	7	-2	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVR's revenue (10.3% per year) is forecast to grow faster than the Australian market (4.9% per year).

High Growth Revenue: AVR's revenue (10.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AVR is forecast to be unprofitable in 3 years.

Anteris Technologies Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies